文献速递白血病

接受初始伊马替尼治疗的慢性髓性白血病患者治疗失败预测评分系统

A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.
PubMed 文献 · Leukemia · 2022-02-22

研究基于1364例连续接受初始伊马替尼治疗的慢性期慢性髓性白血病(CML)患者数据,随机分为训练集(908例)和验证集(456例),识别与无失败生存(FFS)显著相关的协变量并构建IMTF模型。模型在训练集1、3、5年FFS的AUC为0.79-0.84,验证集为0.78-0.85,校准图显示预测与观察结果高度一致,5个风险组的治疗失败累积发生率和FFS概率均有显著差异(所有p值<0.001)。

要点

  • IMTF模型纳入WBC≥120×10E+9/L、血红蛋白<115 g/L、血嗜碱性粒细胞≥12%及ELTS风险评分。
  • 训练集1、3、5年FFS的AUC为0.79-0.84,验证集为0.78-0.85。
  • 5个风险组的伊马替尼治疗失败累积发生率和FFS概率均有显著差异(所有p值<0.001)。

核心结论

  • 这些数据应有助于医生在诊断时优化慢性期CML患者的TKI治疗策略。

研究设计与样本

  • 研究分析了1364例连续接受初始伊马替尼治疗的慢性期CML患者数据,随机分为训练集(n=908)和验证集(n=456)。

主要发现

  • 在训练集中,WBC计数≥120×10E+9/L、血红蛋白浓度<115 g/L、血嗜碱性粒细胞≥12%和ELTS风险评分与无失败生存(FFS)显著相关。
  • 除ELTS高风险类别根据多变量回归系数赋2分外,每个协变量赋1分以构建伊马替尼治疗失败(IMTF)模型。
  • IMTF模型在训练集1、3、5年FFS的AUC为0.79-0.84,在验证集为0.78-0.85。
  • 校准图显示预测结果与观察结果高度一致,决策曲线分析表明受试者从该模型的临床使用中获益。
  • 使用IMTF模型的5个风险队列(极低危、低危、中危、高危和极高危)的伊马替尼治疗失败累积发生率和FFS概率均有显著差异(所有p值<0.001)。

关键数值与推荐

  • IMTF模型赋值:WBC计数≥120×10E+9/L、血红蛋白浓度<115 g/L、血嗜碱性粒细胞≥12%各赋1分,ELTS高风险类别赋2分。
  • 训练集1、3、5年FFS的AUC为0.79-0.84,验证集为0.78-0.85。
  • 5个风险组的治疗失败累积发生率和FFS概率比较,所有p值<0.001。

临床怎么用

  • 作者认为这些数据应有助于医生在诊断时优化慢性期CML患者的TKI治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data from 1,364 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib-therapy were interrogated to identify co-variates predicting therapy failure. Subjects were randomly divided into training (n = 908) and validation datasets (n = 456). In the training dataset, WBC count ≥120 × 10E + 9/L, haemoglobin concentration <115 g/L, blood basophils ≥12% and European Treatment and Outcome Study for CML Long-Term Survival (ELTS) risk score were significantly-associated with failure-free survival (FFS). Each co-variate was assigned 1 point to develop the imatinib-therapy failure (IMTF) model except ELTS high-risk category which was assigned 2 points based on multi-variable regression coefficients. Area under receiver-operator characteristic curve values in the IMTF model for 1-, 3- and 5-year FFS were 0.79-0.84 in the training dataset and 0.78-0.85 in the validation dataset. Calibration plots showed high agreement between predicted and observed outcomes. Decision curve analyses indicated subjects benefited from clinical use of this model. Cumulative incidences of imatinib-therapy failure and probabilities of FFS among the 5 risk cohorts (very low-, low-, intermediate-, high- and very high-risk) using the IMTF model were significantly different (all p values < 0.001). The IMTF model also correlated with probabilities of progression-free survival and survival (all p values < 0.001). These data should help physicians optimize TKI-therapy strategy at diagnosis in persons with chronic phase CML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang XS, Gale RP, Zhang MJ, et al. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022. PMID: 35194158. doi:10.1038/s41375-022-01527-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。